The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CVM | -66.57% | -97.64% | -52.74% | -100% |
| S&P | +14.5% | +93.32% | +14.09% | +1,519% |
CEL-SCI Corp. is a biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients and CEL-2000 and CEL-4000, which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.
The company attempted to clarify "confusion" related to its recent late-stage clinical results.
Everything went the wrong way for Cel-Sci.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.96M | 2.5% |
| Market Cap | $11.76M | -81.3% |
| Net Income | -$5.66M | 17.4% |
| EBITDA | -$4.53M | 20.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $1.79M | 366.1% |
| Inventory | 0.5 | -79.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $7.57M | -24.0% |
| Short Term Debt | $2.39M | 10.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -114.49% | -13.6% |
| Return On Invested Capital | -94.88% | -0.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$3.94M | 13.7% |
| Operating Free Cash Flow | -$3.94M | 13.3% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 5.25 | 2.58 | 2.43 | 0.81 | -81.64% |
| Price to Tangible Book Value | 207.88 | 78.43 | 45.26 | 0.82 | -99.39% |
| Enterprise Value to EBITDA | -14.53 | -5.53 | -5.18 | -3.90 | -70.16% |
| Return on Equity | -206.4% | -227.8% | -238.6% | -328.0% | 34.15% |
| Total Debt | $11.62M | $11.09M | $10.53M | $9.96M | -17.87% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
